Interim Report January-September 2020
Abliva conducts extensive research and development work. This work is done in-house and in collaboration with international partners in Europe, Asia and North America. These partnerships cover pre-clinical development work and clinical trials at renowned hospitals.
More than ten Abliva employees are active in preclinical and clinical development, as well as a number of external consultants engaged on the company’s projects. The company possesses a high level of expertise. All employees are science graduates, with five holding PhDs in medical sciences. Most of the company’s researchers are qualified physicians engaged in identifying segments with unmet medical needs, early basic research and clinical research towards approval of drug candidates.
Because of its unique research, Abliva has established good relationships with the academic and business community across the world, in Europe, Asia and the US, which has created great potential for successful partnerships.
Isomerase of the UK is one of Abliva’s key partners. This collaboration focuses primarily on development of Abliva’s chemistry platforms, i.e. producing active compounds for treating ischemic stroke and mitochondrial disorders, and compounds for organ protection. The collaboration between the two companies’ researchers is also a creative hotbed for identifying new development platforms in indications with a pressing medical need, and with its drug development expertise, Isomerase offers valuable backing for Abliva’s projects. Abliva’s partnership with Isomerase was reinforced in early-2016 through a partial acquisition.
Abliva collaborates with the Korean pharmaceutical company Yungjin Pharm around the clinical development of the KL1333 project for the treatment of primary mitochondrial disorders. Abliva also partners with PENN (the University of Pennsylvania), CHOP (Children’s Hospital of Philadelphia), Karolinska Institutet and a range of contract research organizations, such as Covance in the Netherlands and Patheon in the UK. Abliva has also entered into a commercial partnership with Oroboros Instruments in Austria.
June 18, 2018, Abliva molecules from the NVP015 project was out-licensed for a local treatment of Leber’s hereditary optic neuropathy (LHON) to BridgeBio Pharma’s new subsidiary Fortify Therapeutics. Fortify’s ambition is to further develop the in-licensed NVP015 chemistry in order to establish a therapy for LHON.
In addition to these partners, Abliva collaborates with a range of academic institutions all over the world.